Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

Statistically Significant Improvement in the Primary Endpoint of Overall Survival in Menkes ~ ~ Disease Patients who Received Early Treatment with CUTX-101, Compared to an Untreated Historical Control, with a Nearly 80% Reduction in the Risk of Death (Hazard Ratio = 0.21, p<0.0001) ~ Rolling Submission of New Drug Application to the FDA for CUTX-101 on Track to Begin in the Fourth Quarter of 2020

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here